Join us at the World Orphan Drug Congress!
The two 40-minute roundtable discussions which take place on the 20th and 21st of April focus on the topic of market access in Germany for orphan drugs and the lessons learned from the AMNOG process as well as on European market access- effective strategies for setting drug prices and achieving reimbursement of orphan drugs.
The orphan drug industry has matured considerably in the past decade. With that, more orphan drugs get approved, while pharma and biotechs get closer to launch new and innovative therapies for rare disease patients. Their focus has shifted from early stage challenges to strategies on commercialization, marketing, pricing and reimbursement. The World Orphan Drug Congress unites more than 150 elite speakers to educate and inspire the 1,000 attendees from big pharma, biotech, payers, patient groups, academics and government bodies.
In 2017, The World Orphan Drug Congress is bringing together the worlds of Scientific Innovation and Commercialization, with 2 tracks in the main conference.
By exploring trends in Digital Health, Biosimilars, Gene Therapy, and more, the next scientific breakthrough will be uncovered at the Congress. Examinations of Mergers, Commercialization, Marketing and the Regional Markets will provide insight into this multi-billion-dollar business.
To read more/find out more about the speakers, subjects, workshops and other roundtables, please download the full brochure: http://terrapinn-cdn.com/conference/world-orphan-drug-congress-usa/Data/brochure2017.pdf
Tickets are still available at: http://www.terrapinn.com/conference/world-orphan-drug-congress-usa/index.stm.